Minnesota is currently home to 2064 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Minneapolis Clinic of Neurology, Burnsville, Minnesota
Conditions: Focal Onset Seizures
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
02/28/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: H3 K27M, Glioma
Register for Updates
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
NCT04919226
Recruiting
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Mayo Clinic - Rochester, Department of Oncology, Rochester, Minnesota
Conditions: Neuroendocrine Tumors
Register for Updates
TTVR Early Feasibility Study
NCT04433065
Recruiting
The objective of this early feasibility study is to gain early clinical insight into the performance of the Intrepid transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid valve.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Abbott Northwestern Hospital, Minneapolis, Minnesota
Conditions: Tricuspid Regurgitation
Register for Updates
Longitudinal Study of the Porphyrias
NCT01561157
Recruiting
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
Gender:
ALL
Ages:
1 minute and above
Trial Updated:
02/28/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Porphyrias, Cutaneous Porphyrias
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Research Site, Duluth, Minnesota
Conditions: Non-small Cell Lung Cancer
Register for Updates
US National TOP Registry
NCT06513091
Recruiting
The objective of this Registry is to collect short and long-term post-transplant clinical outcome data of all donor lungs preserved and assessed on the OCS Lung System and to document the performance of the OCS device in the real-world setting after FDA approval in the US.
Gender:
ALL
Ages:
All
Trial Updated:
02/27/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Lung Transplant
Register for Updates
Defining Musical Toxicity and Its Effect on Patient Well-being
NCT06494046
Recruiting
This study evaluates the experience of musicians who are going through cancer treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Breast Carcinoma, Esophageal Carcinoma, Head and Neck Carcinoma, Lung Carcinoma, Malignant Brain Neoplasm, Malignant Solid Neoplasm
Register for Updates
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)
NCT06482073
Recruiting
This study evaluates the effectiveness of robotic biopsies in providing information about hereditary or cancer specific genetic variants that may have a role in diagnosis of cancer and to develop genetic results and medical record databank for future studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Lung Carcinoma, Metastatic Malignant Neoplasm in the Lung
Register for Updates
Insomnia in Patients With Metastatic Lung Cancer
NCT06472804
Recruiting
This study evaluates how common insomnia (difficulties with sleep) is in patients with lung cancer that has spread from where it first started (primary site) to other places in the body.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma
NCT06409013
Recruiting
This study evaluates the effectiveness of intraoperative indocyanine green dye and fluoroscopic technology in confirming negative margins after tumor removal.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Bone Sarcoma, Soft Tissue Sarcoma
Register for Updates
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Clinical Research Institute, Minneapolis, Minnesota
Conditions: Perennial Allergic Rhinitis (PAR)
Register for Updates